

Online Supplementary Material

Validation of a Model Estimating the Budget Impact of Video Capsule Endoscopy for Surveillance of Crohn's Disease in an Italian Center. *JHEOR*. 2024;11(1):67-74. <u>doi:10.36469/jheor.2024.92880</u>

Table S1: Markov Model Transition Probability

Table S2: Crohn's Disease Location Transitions

Table S3: Cost Inputs

Table S4: Permissive and Restrictive Outcome Definitions

Figure S1: One-Way Sensitivity Analysis

Figure S2: Flow Plan of the Analysis

This supplementary material has been provided by the authors to give readers additional information about their work.



Table S1. Markov Model Transition Probability

Markov Model States	Undiagnosed CD	Remission	Non-Active Symptomatic	Active Symptomatic	Active Nonsymptomatic	GI Hemorrhage	Treatment	Treatment Failure	Surgery	Post- surgery	Death
Undiagnosed CD	0.725660555	0	0	0	0.011904762	0	0.2420711	0	0.020363614	0	0
Remission	0	0.823549	0.058816991	0.058816991	0.058816991	0	0	0	0	0	0
Non-active symptomatic	0	0.1647927	0.534319235	0.058816991	0	0	0.2420711	0	0	0	0
Active symptomatic	0	0.1647927	0.013678085	0.379475333	0.164792705	0.01482649	0.2420711	0	0.020363614	0	0
Active non-symptomatic	0	0.1647927	0	0.164792705	0.623319724	0.01482649	0.0119048	0	0.020363614	0	0
GI hemorrhage	0	0	0	0	0	0	0.8	0	0.2	0	0
Treatment	0	0.0599244	0	0	0	0	0.7680927	0.171982879	0	0	0
Treatment failure	0	0	0	0	0	0	0.9796364	0	0.020363614	0	0
Surgery	0	0	0	0	0	0	0	0	0	1	0
Post-surgery	0	0.127316	0	0	0.07884413	0	0.6453102	0	0.148529659	0	0
Death	0	0	0	0	0	0	0	0	0	0	1

Abbreviations: CD, Crohn's disease; GI, gastrointestinal.

Table S2. Crohn's Disease Location Transitions				
Location Transitions	L1	L2	L3	L4
L1	0.963333235	0.0122223	0.012222255	0.012222255
L2	0	0.98890807	0.005545966	0.005545966
L3	0	0	0.996986405	0.003013595
L4	0	0	0	1

Table S3. Cost Inputs

Table 55. Cost inputs			
Item	Costs € (DRG code)		
Ileocolonoscopy, per procedure	74.00 (45.23) ²⁸		
VCE, per procedure	850.00 (45.13.1) ²⁸		
Patency capsule, per procedure	133.8329		
MRE, per procedure	160.10 (88.95.4) ²⁸		
Fecal calprotectin test, per procedure	12.05 (90.12.A Veneto) ³⁰		
CRP test	5.00 (90.72.3) ²⁸		
Infliximab, per year	12254.40ª		
Infliximab, administration cost	10.65 (99.25) ²⁸		
Adalimumab, per year	10197.29ª		
Adalimumab, administration cost	8.50 (99.29.5) ¹		
Vedolizumab, per year	15 349.06ª		
Vedolizumab, administration cost	10.65 (99.25) ¹		
5-ASA, per year	10.96ª		
5-ASA, administration cost	_		
Corticosteroids, per year	29.22ª		
Corticosteroids, administration cost	_		
Azathioprine, per year	255.68ª		
Azathioprine, administration cost	_		
Open bowel surgery	7611.36 ²		
Abscess drainage	4812.69 (171) ²		
Fistula repair	5514.36 (156) ²		
Stricturing repair	4805.04 (153) ²		
Capsule retention	914.83 (189) ²		
Bowel perforation	914.83 (189) ²		

Abbreviations: ASA, 5-aminosalicylic acid; CRP, C-reactive protein; MRE, magnetic resonance enterography; VCE, video capsule endoscopy. aBiologics and conventional annual costs from 2023 wholesale prices.

REFERENCES


1. Regione Emilia Romagna. PRESTAZIONI DI ASSISTENZA SPECIALISTICA AMBULATORIALE, ottobre 2022. Accessed September 19, 2023. <u>https://salute.regione.emilia-romagna.it/ssr/strumenti-e-informazioni/nomenclatore-tariffario-rer/ottobre-2022</u>

2. Regione Emilian Romagna. DRG 2023 - 878.

Table S4. Permissive and Restrictive Outcome Definitions						
		Biologics	Surgery	Remission		
Permissive	Model Continuous 6-month use (2 consecutive intervals)		Keep all (fistulectomy, emergency, elective)	Consecutive 6-month period CDAI ≤150		
	RWD	Continuous 6-month use (1 interval)	All non-missing	Any 6 months CDAI ≤ 150		
Restrictive	Model	Minimum 1-year continuous use (4 consecutive intervals)	Keep only elective and emergency surgery (state "i")	Consecutive 1-year period CDAI ≤150		
	RWD	Minimum 1-year continuous use (2 consecutive intervals)	Drop fistulectomies (keep only "yes")	Consecutive 1-year period CDAI ≤150		

Abbreviation: RWD, real-world data.


Figure S1. One-Way Sensitivity Analysis



This figure presents the impact of a ±20% variation in relevant cost inputs on the base case results (5-year total cost difference between standard of care and VCE). Positive values favor VCE.

Abbreviations: CT, computer tomography; MRE, magnetic resonance enterography; VCE, video capsule endoscopy.

Figure S2. Flow Plan of the Analysis



Flow plan shows analysis from acquiring pseudonymized real patient data to comparing outcomes with model-generated data on patients after applying selection criteria.